TEK and colorectal carcinoma: Plasma Tie2 concentrations rose slightly in patients treated with cytotoxic chemotherapy but significantly reduced (p = 0.004) in patients who received cediranib, in a manner that resembled our findings in OC/CRC patients treated with bevacizumab.